Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more...

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing...

CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in...

Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute. Under the partnership, Seqirus will participate in research projects and knowledge generation around both the threat of seasonal influenza and the development of innovative approaches to pandemic preparedness and response.

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response...

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for...